<DOC>
	<DOCNO>NCT02013648</DOCNO>
	<brief_summary>This randomized phase III open-label , multicenter trial evaluate standard induction therapy ( daunorubicin [ DNR ] cytarabine [ Ara-C ] ) consolidation therapy ( high-dose cytarabine [ HDAC ] ) without dasatinib adult patient newly diagnose CBF-AML</brief_summary>
	<brief_title>Randomized Phase III Study Intensive Chemotherapy With Without Dasatinib ( Sprycel™ )</brief_title>
	<detailed_description>This randomized phase III open-label , multicenter trial evaluate standard induction therapy ( daunorubicin [ DNR ] cytarabine [ Ara-C ] ) consolidation therapy ( high-dose cytarabine [ HDAC ] ) without dasatinib adult patient newly diagnose CBF-AML ; investigational arm , consolidation therapy follow one-year maintenance therapy dasatinib . Patients molecular disease persistence molecular relapse assess quantitative RQ-PCR CBF fusion transcript eligible hematopoietic stem cell transplantation overt hematologic relapse occur . Primary endpoint event-free survival . AML patient assess CBF fusion gene one two AMLSG central laboratory within 48 hour diagnosis , patient CBF-AML enrol .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Corebinding factor ( CBF ) AML molecular diagnosis RUNX1RUNX1T1 fusion transcript result ( 8 ; 21 ) ( q22 ; q22 ) ( variant form ) CBFBMYH11 fusion transcript result inv ( 16 ) ( p13.1q22 ) /t ( 16 ; 16 ) ( p13.1 ; q22 ) assess one central AMLSG reference laboratory ( Ulm , Hannover ) Age ≥ 18 ; upper age limit No prior chemotherapy leukemia except hydroxyurea 5 day diagnostic screen phase Nonpregnant nonnursing . Due unknown teratogenic potential dasatinib human , pregnant nursing patient may enrol . Women childbearing potential ( WOCBP ) must negative serum urine pregnancy test within sensitivity least 25 mIU/mL within 72 hour prior registration . Women childbearing potential must either commit continued abstinence heterosexual intercourse begin TWO acceptable method birth control one highly effective method ( e.g. , IUD , hormonal , tubal ligation , partner 's vasectomy ) , one additional effective method ( e.g. , latex condom , diaphragm , cervical cap ) AT THE SAME TIME , least four week begin dasatinib therapy . `` Women childbearing potential '' define sexually active mature woman undergone hysterectomy menses time precede 24 consecutive month . Men must agree father child must use latex condom sexual contact woman childbearing potential take dasatinib 3 month therapy stop , even undergone successful vasectomy . Signed write informed consent . Performance status WHO &gt; 2 Pulmonary edema and/or pleural/pericardial effusion within 14 day day 1 . If edema/effusion resolve CTC Grade ≤1 , patient treat dasatinib . Patients ejection fraction &lt; 50 % echocardiography within 14 day day 1 Organ insufficiency ( creatinine &gt; 1.5x upper normal serum level ; bilirubin , AST AP &gt; 2.5x upper normal serum level ; heart failure NYHA III/IV ; severe obstructive restrictive ventilation disorder ) Uncontrolled infection Patients `` currently active '' second malignancy nonmelanoma skin cancer . Patients consider `` currently active '' malignancy , complete therapy consider physician less 30 % risk relapse within one year . Severe neurological psychiatric disorder interfere ability give informed consent Known positive HIV , active HBV , HCV , Hepatitis A infection Bleeding disorder independent leukemia No consent registration , storage process individual disease characteristic course well information family physician and/or physician involve treatment patient study participation . No consent biobanking .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>AML</keyword>
	<keyword>Dasatinib</keyword>
	<keyword>Core Binding Factor ( CBF )</keyword>
</DOC>